Protagonist Therapeutics, Inc. (PTGX)
Largest Insider Buys in Sector
PTGX Stock Price History Chart
PTGX Stock Performance
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II …
Insider Activity of Protagonist Therapeutics, Inc.
Over the last 12 months, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $7.34M worth of Protagonist Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protagonist Therapeutics, Inc. have bought $908,814 and sold $2.35M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 24,000 shares for transaction amount of $160,800 was made by SELICK HAROLD E (director) on 2020‑03‑12.
List of Insider Buy and Sell Transactions, Protagonist Therapeutics, Inc.
| 2024-09-11 | Sale | Chief Financial Officer | 14,203 0.0239% | $44.49 | $631,872 | 0.00% | ||
| 2024-09-10 | Sale | director | 8,000 0.0136% | $45.00 | $360,000 | +2.14% | ||
| 2024-07-24 | Sale | director | 8,000 0.013% | $40.00 | $320,000 | 0.00% | ||
| 2024-06-07 | Sale | President and CEO | 35,000 0.0603% | $35.19 | $1.23M | +20.57% | ||
| 2024-06-07 | Sale | director | 8,000 0.0137% | $35.00 | $280,000 | +20.57% | ||
| 2024-04-18 | Sale | Chief Financial Officer | 1,234 0.0021% | $25.11 | $30,986 | +47.36% | ||
| 2024-04-01 | Sale | President and CEO | 25,000 0.0429% | $28.31 | $707,750 | +25.99% | ||
| 2024-03-01 | Sale | President and CEO | 30,000 0.051% | $31.62 | $948,600 | +1.18% | ||
| 2024-03-01 | Sale | Chief Financial Officer | 14,248 0.0247% | $32.24 | $459,318 | +1.18% | ||
| 2024-03-01 | Sale | director | 12,975 0.0219% | $31.34 | $406,637 | +1.18% | ||
| 2024-02-29 | Sale | Chief Financial Officer | 9,939 0.0174% | $30.69 | $305,048 | +6.99% | ||
| 2024-01-09 | Sale | Chief Development Officer | 5,000 0.0084% | $25.00 | $125,000 | +18.12% | ||
| 2023-12-13 | Sale | President and CEO | 75,000 0.1305% | $20.08 | $1.51M | +48.98% | ||
| 2023-11-15 | Sale | Chief Medical Officer | 1,848 0.0032% | $16.24 | $30,012 | +75.95% | ||
| 2021-12-21 | Sale | President and CEO | 15,000 0.0311% | $32.14 | $482,171 | -70.97% | ||
| 2021-08-17 | Sale | Chief Scientific Officer | 14,779 0.0303% | $47.56 | $702,889 | -47.52% | ||
| 2021-02-11 | Sale | director | 3,700 0.0084% | $25.09 | $92,833 | +29.81% | ||
| 2021-02-10 | Sale | director | 4,700 0.011% | $25.47 | $119,722 | +32.45% | ||
| 2021-01-19 | Sale | President and CEO | 24,846 0.0557% | $24.60 | $611,105 | +31.22% | ||
| 2020-08-11 | Sale | director | 2,499 0.0068% | $17.19 | $42,952 | +47.14% |
Insider Historical Profitability
| PATEL DINESH V PH D | President and CEO | 515415 0.875% | $47.19 | 1 | 11 | +243.28% |
| Gupta Suneel | Chief Development Officer | 187567 0.3184% | $47.19 | 1 | 1 | +243.28% |
| Papanek Julie | director | 2453255 4.1648% | $47.19 | 1 | 0 | +18.24% |
| JOHNSON & JOHNSON | 10 percent owner | 2449183 4.1579% | $47.19 | 1 | 0 | +18.24% |
| CANAAN X L.P. | 10 percent owner | 2116552 3.5932% | $47.19 | 1 | 13 | +18.24% |
Institutional Investor Ownership
| Farallon Capital | $166.03M | 9.79 | 5.74M | +0.08% | +$131,428.99 | 1.17 | |
| BlackRock | $161.13M | 9.5 | 5.57M | +0.46% | +$740,116.19 | <0.01 | |
| RTW Investments, LP | $153.78M | 9.06 | 5.32M | 0% | +$0 | 2.3 | |
| Bvf Inc Il | $108.66M | 6.4 | 3.76M | -34.62% | -$57.54M | 0.8 | |
| State Street | $94.67M | 5.58 | 3.27M | +19.87% | +$15.7M | <0.01 |